tiprankstipranks
E-Therapeutics PLC (GB:ETX)
LSE:ETX

E Therapeutics (ETX) Financial Statements

5 Followers

E Therapeutics Financial Overview

E Therapeutics's market cap is currently ―. The company's EPS TTM is p-0.017; its P/E ratio is -6.01; E Therapeutics is scheduled to report earnings on October 23, 2024, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.
Jul 22Jan 22Jul 21Jan 21Jul 20
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT-----
EBITDA-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments£ 21.81M£ 26.65M£ 31.61M£ 13.03M£ 15.06M
Total Assets£ 25.55M£ 29.76M£ 33.85M£ 14.31M£ 16.04M
Total Debt£ 494.00K£ 686.00K£ 0.00£ 23.00K£ 46.00K
Net Debt£ -21.32M£ -25.96M£ -31.61M£ -13.00M£ -15.02M
Total Liabilities£ 1.18M£ 1.79M£ 851.00K£ 427.00K£ 432.00K
Stockholders Equity£ 24.36M£ 27.97M£ 33.00M£ 13.88M£ 15.61M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in GBP

E Therapeutics Earnings and Revenue History

E Therapeutics Debt to Assets

E Therapeutics Cash Flow

E Therapeutics Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis